Does This 1 Number Mean Trouble for Moderna?
Moderna (NASDAQ: MRNA) generated billions of dollars from its sale of coronavirus vaccines earlier in the pandemic. Today, most of the people who wanted the primary vaccine series have gotten it. But that doesn't mean Moderna's revenue opportunity is over.
The biotech's next revenue driver is selling a strain-specific booster. Regulators gave the omicron booster a thumbs-up this summer. And the product made it to market in time for the fall vaccination season. Still, one particular number doesn't look so brilliant. Could it mean trouble for Moderna?
I'm talking about the number of people who have received Moderna's strain-specific booster. The U.S. Food and Drug Administration (FDA) recently extended its authorization of the booster to include people ages six and older. But initially, the FDA gave the nod only for use in adults. So, we'll look at the percentage of adults who have received Moderna's updated shot.
Source Fool.com
